Quel est le prix pour Sigilon Therapeutics, Inc. (SGTX)

Le prix pour Sigilon Therapeutics, Inc. (SGTX) est $22.47

Quelle est la capitalisation boursière pour Sigilon Therapeutics, Inc. (SGTX)

La capitalisation boursière pour Sigilon Therapeutics, Inc. (SGTX) est $49.76M

Sigilon Therapeutics, Inc. (SGTX) Prix et Capitalisation Boursière

Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.

Prix pour SGTX	L’actif B	La capitalisation boursière de B	Résultats
$2,373,665 $49.76M	NVDA	$5.257T	+10,563,608.72%
$2,076,464 $49.76M	AAPL	$4.599T	+9,240,948.75%
$1,854,276 $49.76M	GOOG	$4.107T	+8,252,130.22%
$1,615,264 $49.76M	MSFT	$3.577T	+7,188,435.39%
$1,267,604 $49.76M	AMZN	$2.807T	+5,641,215.17%

Prix pour SGTX

L’actif B

La capitalisation boursière de B

Résultats

$2,373,665 $49.76M